H2 tag- SEO Purpose
GERD: Gastroesophageal reflux disease; PCAB: Potassium competitive acid blockers; PPI: Proton pump inhibitor. pump inhibitor; RH: Reflux hypersensitivity; RSA: Reflux symptom association, VONOPrazan.
Despite PPIs being the most effective treatment for GERD, up to 30% of GERD patients experience refractory GERD.1
Several factors contribute to refractory GERD that vary in incidence, clinical importance, and symptom severity and frequency.1
PPI timing: Only 46% of patients dosed PPIs at appropriate times.2
PPI compliance: Only ~54% of patients filled their monthly PPI prescription >80% of the time.2
Acid pocket: PPI use can reduce the size of acid pocket and increase gastric pH.2
Cytochrome P450 2C19 polymorphism: PPI response varies by genotype; extensive metabolizers are more likely to have refractory symptoms on standard-dose.2
With PCABs offering potent acid suppression from the first dose, they may soon replace PPIs as the preferred initial therapy.3 A single dose of VONOprazan can raise intragastric pH to nearly 7 within 4 hours.4
As shown in the figure, VONOprazan’s ability to maintain a 24-hour intragastric pH above 4 ensures rapid and sustained relief, making it suitable for treating breakthrough GERD symptoms and for on-demand therapy.
Vono 20-Always on Duty
Vono, containing Vonoprazan molecule, is a Potassium Competitive Acid Blocker which helps in treatment of Refractory GERD, Erosive Esophagitis, H.Pylori, Gastric & Duodenal Ulcers
